GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BLIS Technologies Ltd (NZSE:BLT) » Definitions » Current Ratio

BLIS Technologies (NZSE:BLT) Current Ratio : 8.88 (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is BLIS Technologies Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. BLIS Technologies's current ratio for the quarter that ended in Mar. 2024 was 8.88.

BLIS Technologies has a current ratio of 8.88. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for BLIS Technologies's Current Ratio or its related term are showing as below:

NZSE:BLT' s Current Ratio Range Over the Past 10 Years
Min: 2.4   Med: 5.57   Max: 14.17
Current: 6.59

During the past 13 years, BLIS Technologies's highest Current Ratio was 14.17. The lowest was 2.40. And the median was 5.57.

NZSE:BLT's Current Ratio is ranked better than
68.71% of 1547 companies
in the Biotechnology industry
Industry Median: 3.8 vs NZSE:BLT: 6.59

BLIS Technologies Current Ratio Historical Data

The historical data trend for BLIS Technologies's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BLIS Technologies Current Ratio Chart

BLIS Technologies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.50 2.84 7.75 6.86 8.88

BLIS Technologies Semi-Annual Data
Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.75 6.65 6.86 6.59 8.88

Competitive Comparison of BLIS Technologies's Current Ratio

For the Biotechnology subindustry, BLIS Technologies's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BLIS Technologies's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BLIS Technologies's Current Ratio distribution charts can be found below:

* The bar in red indicates where BLIS Technologies's Current Ratio falls into.



BLIS Technologies Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

BLIS Technologies's Current Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Current Ratio (A: Mar. 2024 )=Total Current Assets (A: Mar. 2024 )/Total Current Liabilities (A: Mar. 2024 )
=10.951/1.233
=8.88

BLIS Technologies's Current Ratio for the quarter that ended in Mar. 2024 is calculated as

Current Ratio (Q: Mar. 2024 )=Total Current Assets (Q: Mar. 2024 )/Total Current Liabilities (Q: Mar. 2024 )
=10.951/1.233
=8.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BLIS Technologies  (NZSE:BLT) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


BLIS Technologies Current Ratio Related Terms

Thank you for viewing the detailed overview of BLIS Technologies's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BLIS Technologies (NZSE:BLT) Business Description

Traded in Other Exchanges
N/A
Address
442 Moray Place, Ground Floor, Dunedin, OTA, NZL, 9016
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets two strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18 both of which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from EMEA (Europe, the Middle East, and Africa).

BLIS Technologies (NZSE:BLT) Headlines

From GuruFocus

Bill Nygren's Oakmark Comments on Blount International

By Holly LaFon Holly LaFon 07-10-2012

Ariel Fund Quarterly Commentary From John Rogers

By Holly LaFon Holly LaFon 01-21-2016

Olstein Strategic Opportunities Fund 2014 Investor Letter

By Canadian Value Canadian Value 04-01-2015

John Rogers Comments on Blount Intl Inc.

By Holly LaFon Holly LaFon 01-22-2016

Blount International Inc. (BLT) CEO Joshua L Collins buys 10,000 Shares

By GuruFocus Research GuruFocus Editor 10-13-2009

Blount International Inc. (BLT) CEO Joshua L Collins buys 5,000 Shares

By GuruFocus Research GuruFocus Editor 06-17-2010

John Rogers' Recent Trades

By Tiziano Frateschi Tiziano Frateschi 04-06-2016